Rotavirus vaccine product switch in Ghana: An assessment of service delivery costs, switching costs, and cost-effectiveness.
Richmond Owusu, Mercy Mvundura, Justice Nonvignon, George Armah, John Bawa, Kwadwo Odei Antwi-Agyei, Kwame Amponsa-Achiano, Frederick Dadzie, George Bonsu, Andrew Clark, Clint Pecenka, Frederic Debellut
Author Information
Richmond Owusu: School of Public Health, University of Ghana, Accra, Ghana.
Mercy Mvundura: Center for Vaccine Innovation and Access, PATH, Seattle, Washington, United States of America. ORCID
Justice Nonvignon: School of Public Health, University of Ghana, Accra, Ghana. ORCID
George Armah: Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
John Bawa: Center for Vaccine Innovation and Access, PATH, Accra, Ghana.
Kwadwo Odei Antwi-Agyei: Center for Vaccine Innovation and Access, PATH, Accra, Ghana.
Kwame Amponsa-Achiano: Expanded Programme on Immunization, Ghana Health Service, Accra, Ghana.
Frederick Dadzie: Expanded Programme on Immunization, Ghana Health Service, Accra, Ghana.
George Bonsu: Expanded Programme on Immunization, Ghana Health Service, Accra, Ghana.
Andrew Clark: Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Clint Pecenka: Center for Vaccine Innovation and Access, PATH, Seattle, Washington, United States of America.
Frederic Debellut: Center for Vaccine Innovation and Access, PATH, Geneva, Switzerland. ORCID
Ghana introduced rotavirus vaccine (ROTARIX 1-dose presentation) into the routine national immunization program in 2012 and switched to a different product (ROTAVAC 5-dose presentation) in 2020. ROTAVAC has a lower price per dose (US$0.85 versus US$2.15 for ROTARIX) and smaller cold chain footprint but requires more doses per regimen (three versus two). This study estimates the supply chain and service delivery costs associated with each product, the costs involved in switching products, and compares the cost-effectiveness of both products over the next ten years. We estimated the supply chain and service delivery costs associated with ROTARIX and ROTAVAC (evaluating both the 5-dose and 10-dose presentations) using primary data collected from health facilities in six of the 14 regions in the country. We estimated the costs of switching from ROTARIX to ROTAVAC using information collected from key informant interviews and financial records provided by the government. All costs were reported in 2020 US$. We used the UNIVAC decision-support model to evaluate the cost-effectiveness (US$ per disability-adjusted life-year (DALY) averted from government and societal perspectives) of ROTARIX and ROTAVAC (5-dose or 10-dose presentations) compared to no vaccination, and to each other, over a ten-year period (2020 to 2029). We ran probabilistic sensitivity analyses and other threshold analyses. The supply chain and service delivery economic cost per dose was $2.40 for ROTARIX, $1.81 for ROTAVAC 5-dose, and $1.76 for ROTAVAC 10-dose. The financial and economic cost of switching from ROTARIX to ROTAVAC 5-dose was $453,070 and $883,626, respectively. Compared to no vaccination, the cost per DALY averted was $360 for ROTARIX, $298 for ROTAVAC 5-dose, and $273 for ROTAVAC 10-dose. ROTAVAC 10-dose was the most cost-effective option and would be cost-effective at willingness-to-pay thresholds exceeding 0.12 times the national GDP per capita ($2,206 in the year 2020). The switch from ROTARIX to ROTAVAC 5-dose in 2020 was cost-saving. Rotavirus vaccination is highly cost-effective in Ghana. A switch from ROTAVAC 5-dose to ROTAVAC 10-dose would be cost-saving and should be considered.
